---
figid: PMC3736320__emss-52738-f0001
figlink: /pmc/articles/PMC149053/figure/fig7/
number: ''
caption: '(A) Grey rectangle: mutant BRAF (BRAFV600E) hyper-activates ERK signaling
  and promotes tumor cell proliferation and survival, but BRAF and MEK drugs inhibit
  the pathway and block tumor progression. Main figure: resistance to BRAF inhibitors
  is mediated by several mechanisms, including expression of a truncated forms of
  mutant BRAF, increased expression of mutant BRAF or wild-type CRAF, acquisition
  of mutations in RAS or MEK, expression of MAP3K8/COT, loss of PTEN expression, or
  activation of the receptor tyrosine kinases PDGFRβ, IGF-1R, EGFR and HER2/HER3,
  or increased activation of MET through the increased secretion of HGF by the stromal
  compartment.(B) EGF family receptors mediate resistance to BRAF inhibitors. In colorectal
  cells BRAF inhibits HER1 by inducing CDC25C, so BRAF inhibition by vemurafenib (Vem)
  releases the block to HER1 activation by reducing CDC25C expression. In thyroid
  cancer cells HER3 expression is inhibited by BRAF through the CtBP1/2 transcription
  repressors, so BRAF inhibition by vemurafenib (Vem) results in increased HER3 expression,
  and it alsoincreases NRG1 expression through unknown mechanisms. In melanoma, BRAF
  inhibition by vemurafenib (Vem) drives HER1 signaling by increasing EGF secretion,
  increasing HER1 expression and suppressing MIG6 activity through unknown mechanisms.'
pmcid: PMC3736320
papertitle: 'Déjà vu: EGF receptors drive resistance to BRAF inhibitors.'
reftext: Maria Romina Girotti, et al. Cancer Discov. ;3(5):487-490.
pmc_ranked_result_index: '59383'
pathway_score: 0.9549356
filename: emss-52738-f0001.jpg
figtitle: 'Déjà vu: EGF receptors drive resistance to BRAF inhibitors'
year: ''
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3736320__emss-52738-f0001.html
  '@type': Dataset
  description: '(A) Grey rectangle: mutant BRAF (BRAFV600E) hyper-activates ERK signaling
    and promotes tumor cell proliferation and survival, but BRAF and MEK drugs inhibit
    the pathway and block tumor progression. Main figure: resistance to BRAF inhibitors
    is mediated by several mechanisms, including expression of a truncated forms of
    mutant BRAF, increased expression of mutant BRAF or wild-type CRAF, acquisition
    of mutations in RAS or MEK, expression of MAP3K8/COT, loss of PTEN expression,
    or activation of the receptor tyrosine kinases PDGFRβ, IGF-1R, EGFR and HER2/HER3,
    or increased activation of MET through the increased secretion of HGF by the stromal
    compartment.(B) EGF family receptors mediate resistance to BRAF inhibitors. In
    colorectal cells BRAF inhibits HER1 by inducing CDC25C, so BRAF inhibition by
    vemurafenib (Vem) releases the block to HER1 activation by reducing CDC25C expression.
    In thyroid cancer cells HER3 expression is inhibited by BRAF through the CtBP1/2
    transcription repressors, so BRAF inhibition by vemurafenib (Vem) results in increased
    HER3 expression, and it alsoincreases NRG1 expression through unknown mechanisms.
    In melanoma, BRAF inhibition by vemurafenib (Vem) drives HER1 signaling by increasing
    EGF secretion, increasing HER1 expression and suppressing MIG6 activity through
    unknown mechanisms.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CROT
  - IGF1R
  - CDC25C
  - AKT2
  - NRAS
  - MAP2K1
  - RAF1
  - EGF
  - AKT3
  - PIK3CB
  - MAPK1
  - AKT1
  - PIK3R3
  - PTEN
  - PIK3R4
  - KRAS
  - PDGFRB
  - HGF
  - PIK3CA
  - PIK3CD
  - MET
  - PIK3CG
  - MAPK3
  - HRAS
  - ERBB3
  - ERBB2
  - PIK3R5
  - NRG1
  - MAP2K2
  - PIK3R6
  - Selumetinib
  - Trametinib
  - Dabrafenib
  - Cancer
  - Lung cancer
genes:
- word: COT
  symbol: COT
  source: hgnc_alias_symbol
  hgnc_symbol: CROT
  entrez: '54677'
- word: IGF-1R
  symbol: IGF1R
  source: hgnc_symbol
  hgnc_symbol: IGF1R
  entrez: '3480'
- word: CDC25C
  symbol: CDC25C
  source: hgnc_symbol
  hgnc_symbol: CDC25C
  entrez: '995'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: MEK*
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: CRAF
  symbol: c-Raf
  source: hgnc_alias_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: EGF
  symbol: EGF
  source: hgnc_symbol
  hgnc_symbol: EGF
  entrez: '1950'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CB
  entrez: '5291'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R3
  entrez: '8503'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R4
  entrez: '30849'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
- word: PDGFRB
  symbol: PDGFRB
  source: hgnc_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: HGF
  symbol: HGF
  source: hgnc_symbol
  hgnc_symbol: HGF
  entrez: '3082'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CA
  entrez: '5290'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CD
  entrez: '5293'
- word: MET
  symbol: MET
  source: hgnc_symbol
  hgnc_symbol: MET
  entrez: '4233'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3CG
  entrez: '5294'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: HER3
  symbol: HER3
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB3
  entrez: '2065'
- word: HER2
  symbol: HER-2
  source: hgnc_alias_symbol
  hgnc_symbol: ERBB2
  entrez: '2064'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R5
  entrez: '23533'
- word: NRG1
  symbol: NRG1
  source: hgnc_symbol
  hgnc_symbol: NRG1
  entrez: '3084'
- word: MEK*
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: PI3K
  symbol: PI3K
  source: bioentities_symbol
  hgnc_symbol: PIK3R6
  entrez: '146850'
chemicals:
- word: Selumetinib
  source: MESH
  identifier: C517975
- word: Trametinib
  source: MESH
  identifier: C560077
- word: Dabrafenib
  source: MESH
  identifier: C561627
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Lung cancer
  source: ''
  identifier: ''
---
